Table 2.

Main available drugs or candidates against enveloped ssRNA viruses

Virus		Antiviral Mechanisms	Status	Representative Drugsd
(+) ssRNA virus	SARS -CoV-2	• Entry inhibitor	Investigational	• Leronlimab
		• RNA polymerase inhibitors	Investigational /conditionally approved	• Favipiravir[323] • GS-441524	• Remdesivir
		• Inosine-5-monophosphate dehydrogenase (IMPDH) Inhibitor	Investigational	• Merimepodib[324]
	HCV	• NS3/4A protease inhibitors	Approved	• Asunaprevir • Boceprevir • Glecaprevir • Grazoprevir	• Paritaprevir • Simeprevir • Telaprevir • Voxilaprevir
			Investigational	• Faldaprevir	• Vedroprevir
		• NS5B polymerase inhibitors	Approved	• Dasabuvir	• Sofosbuvir
			Investigational	• Beclabuvir	• Uprifosbuvir
		• NS5A inhibitors	Approved	• Elbasvir • Daclatasvir • Ledipasvir	• Ombitasvir • Pibrentasvir • Velpatasvir
			Investigational	• Odalasvir • Ravidasvir	Ruzasvir
		• Interferon α/β receptor agonists	Approved	• Peginterferon α2a • Peginterferon α2b
		• Broad-spectrum activity	Approved	• Ribavirin
	HIV	• Nucleoside and nucleotide reverse transcriptase inhibitors (NRTI)	Approved	• Abacavir • Didanosine • Emtricitabine • Lamivudine	• Stavudine • Tenofovir disoproxil • Zalcitabine • Zidovudine
			Investigational	• Elvucitabine	• Racivir
		• Non-nucleoside reverse transcriptase inhibitors (NNRTI)	Approved	• Delavirdine • Doravirine • Efavirenz	• Etravirine • Nevirapine • Rilpivirine
			Investigational	• Atevirdine • Calanolide A	• UC-781
		• Protease inhibitors	Approved	• Amprenavir • Atazanavir • Darunavir • Fosamprenavir • Indinavir	• Lopinavir • Nelfinavir • Ritonavir • Saquinavir • Tipranavir
			Investigational	• TMC-310911
		• Integrase inhibitors	Approved	• Bictegravir • Dolutegravir	• Elvitegravir • Raltegravir
		• Fusion inhibitor	Approved	• Enfuvirtide
		• Entry inhibitors	Approved	• Maraviroc	• Ibalizumab
			Investigational	• Cenicriviroc	• Leronlimab
		• Others	Investigational	• BMS-488043 • Dexelvucitabine • Fiacitabine	• Lobucavir • Sorivudine
(-) ssRNA virus	RSV	• Fusion inhibitor	Approved	• Palivizumab
		• Broad-spectrum activity	Approved	• Ribavirin
	Influenza virus	• CAP endonuclease inhibitor	Approved	• Baloxavir marboxil
		• Neuraminidase inhibitors	Approved	• Oseltamivir • Peramivir		• Zanamivir
			Investigational	• Laninamivir
		• RNA synthesis inhibitors	Approved	• Rimantadine
			Experimental	• Triazavirin
		• Fusion inhibitor	Investigational	• Umifenovir

^dSummary from DRUGBANK, category of Antiviral Agents (https://www.drugbank.ca/categories/DBCAT000066) when no other reference is provided.³⁴¹